ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,597Medicare Part D Prescriptions Filled, Including Refills

Rank: 253 out of 2035

$485K Total Retail Price of All Prescriptions

Rank: 323 out of 2035

497 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 497 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

14% of this provider’s 497 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

1% of this provider’s 6,520 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
LISINOPRIL 391 303 1 3
LEVOTHYROXINE SODIUM 347 279 2 4
PRAVASTATIN SODIUM 288 244 3 17
OMEPRAZOLE 269 232 4 5
AMLODIPINE BESYLATE 268 231 5 6
ALENDRONATE SODIUM 217 176 6 27
HYDROCODONE-ACETAMINOPHEN 189 121 S3 7 2
FUROSEMIDE 183 156 8 7
ZOLPIDEM TARTRATE 177 115 9 21
METFORMIN HCL 175 97 10 9
CITALOPRAM HBR 160 130 11 20
ATENOLOL 145 141 12 10
SIMVASTATIN 142 121 13 1
GABAPENTIN 132 93 14 14
POTASSIUM CHLORIDE 128 126 15 18
LANTUS SOLOSTAR 127 87 16 66
METOPROLOL TARTRATE 111 98 17 8
MIRTAZAPINE 104 98 18 46
BACLOFEN 100 70 19 112
LOVASTATIN 97 86 20 33
HYDRALAZINE HCL 97 95 20 45
LANTUS 91 49 22 40
LOSARTAN POTASSIUM 91 85 22 15
FLUTICASONE PROPIONATE 90 70 24 29
HYDROCHLOROTHIAZIDE 90 76 24 12
GLIPIZIDE 87 62 26 54
TRAMADOL HCL 86 58 27 19
SERTRALINE HCL 82 37 28 23
AMLODIPINE BESYLATE-BENAZEPRIL 78 74 29 88
WARFARIN SODIUM 77 55 30 11
DONEPEZIL HCL 70 70 31 24
PROAIR HFA 68 43 32 31
METOPROLOL SUCCINATE 63 63 33 16
CARVEDILOL 62 54 34 22
OXYBUTYNIN CHLORIDE ER 60 60 35 117
AZITHROMYCIN 58 51 36 39
TRIAMCINOLONE ACETONIDE 57 46 37 142
ATORVASTATIN CALCIUM 56 43 38 13
EVISTA 54 45 39 136
LANSOPRAZOLE 53 30 40 118
POLYETHYLENE GLYCOL 3350 51 34 41 48
OXYBUTYNIN CHLORIDE 51 40 41 102
DILTIAZEM 24HR CD 51 51 41 122
PREDNISONE 51 43 41 36
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 25, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.